Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337098 | 1.00 | NTRK1 (0.74) | NTRK1GRK6 | |
| SCHEMBL30009939 | 1.00 | NTRK1 (0.74) | NTRK1GRK6 | |
| SCHEMBL4068043 | 0.89 | NTRK1 (0.75) | NTRK1GRK6 | |
| SCHEMBL4076742 | 0.88 | NTRK1 (0.76) | NTRK1GRK6 | |
| SCHEMBL4073738 | 0.87 | NTRK1 (0.56) | NTRK1GRK6 | |
| SCHEMBL4069542 | 0.87 | NTRK1 (0.64) | NTRK1GRK6 | |
| SCHEMBL4156670 | 0.85 | NTRK1 (1.00) | NTRK1 | |
| SCHEMBL4074781 | 0.84 | NTRK1 (0.65) | NTRK1GRK6 | |
| SCHEMBL4065458 | 0.84 | NTRK1 (0.61) | NTRK1GRK6 | |
| SCHEMBL4073723 | 0.84 | NTRK1 (0.53) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | claimed |
| WO-2021072238-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20180142306-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180142306-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885GRK6 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.